

Announcement No. 4/2014

To NASDAQ OMX Copenhagen A/S

Exiqon A/S  
Skelstedet 16  
2950 Vedbæk  
Denmark

Phone: +45 4566 0888  
Fax: +45 4566 1888  
exiqon@exiqon.com  
www.exiqon.com  
CVR/Tax Id: 18 98 44 31

25 March 2014

### **Exiqon A/S – Decisions at annual general meeting 2014**

The annual general meeting of Exiqon A/S was held today, 25 March 2014, at the Company's address, Skelstedet 16, DK-2950 Vedbæk, where the general meeting resolved:

1. To adopt the audited annual report.
2. To appropriate the result of the year as proposed in the audited annual report.
3. To approve the supervisory board's remuneration for 2014 as proposed by the supervisory board.
4. To re-elect Thorleif Krarup, Erik Walldén, Michael Nobel and Per Wold-Olsen as members of the company's supervisory board.
5. To re-appoint Deloitte Statsautoriseret Revisionspartnerselskab as the company's auditor.
8. To adopt the supervisory board's proposal that the company's annual report be prepared and presented in English as of the financial year 2014.
9. To update the provisions in the articles of association regarding warrants as proposed by the supervisory board.
10. To authorise the chairman of the meeting to make amendments and additions to the resolutions adopted in connection with registration thereof.

At a supervisory board meeting held immediately after the general meeting, the supervisory board elected Thorleif Krarup as chairman of the supervisory board and Erik Walldén as vice chairman of the supervisory board. The composition of the supervisory board is, hereafter, as follows:

Thorleif Krarup, chairman  
Erik Walldén, vice chairman  
Michael Nobel  
Per Wold-Olsen

### **Additional information**

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

### **About Exiqon**

Exiqon operates in two business segments: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of research products for microRNA analysis. Exiqon Diagnostics develops novel molecular diagnostic tests for stratification of patients, for clinical trials, early detection of diseases and to help physicians make treatment decisions based on RNA profiling. Exiqon is listed on NASDAQ OMX in Copenhagen. For more information about us, please visit [www.exiqon.com](http://www.exiqon.com).